# A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

> **NCT05472090** · PHASE2 · COMPLETED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
- COVID-19
- Long COVID
- Long Haul COVID

## Interventions

- **DRUG:** TNX-102 SL
- **DRUG:** Placebo SL Tablet

## Key facts

- **NCT ID:** NCT05472090
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-18
- **Primary completion:** 2023-07-12
- **Final completion:** 2023-07-27
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472090, "A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05472090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*